FDA Overreach? Treating your cells as drugs

In today's Wall Street Journal, American Enterprise Institute (AEI) resident fellow and former Food and Drug Administration (FDA) deputy commissioner Scott Gottlieb, MD explains that the FDA's attempt to regulate cells as drugs could halt one of the most promising areas of medical research.


Gottlieb explains:

  • FDA wants to regulate cells: "At issue are cells taken from our own bodies and then re-implanted with the purpose of treating medical problems. The most inspiring work involves adult stem cells, although the court's ruling in principle extends FDA oversight into things as common as in-vitro fertilization--basically turning reproductive cells into "drugs" under the law." Two weeks ago, a United States District Court ruled that adult stem cells are drugs, and thus subject to FDA regulation.
  • FDA regulations hamper unique procedures: "Doctors will now try to convert procedures into products that can fit FDA's regulatory rubric….Not every cell procedure will lend itself to this sort of revision. How, for instance, would you run a large-scale, randomized trial and ensure consistency from one use of a drug to another, where the "drug" is really a medical procedure that must vary from one patient to the next because it involves their own unique cells?"
  • Pushing innovation outside of the Untied States: The company involved in the court case, Regenerative Sciences, has moved some labs to the Cayman Islands. Most of the adult stem cell science research is being done in Britain, Singapore, and Israel "precisely because of the FDA's bent to hold with misgiving anything novel in medicine."



"The FDA is perennially complaining to Congress that it lacks the resources to do its day job of regulating products that fall squarely in its purview. Yet in chorus, the agency is always seeking novel authority to insert itself into new areas of science where its mandate is shaky…[this goal] can be deadly when it comes to the agency's impulse to regulate, and thus forestall, cell therapies used to help repair damaged body parts."


Scott Gottlieb is a practicing physician and resident fellow at the American Enterprise Institute. He was deputy commissioner of the FDA and a senior adviser at the Centers for Medicare and Medicaid Services. He can be reached at [email protected].


For additional help, other media inquiries, or to reserve AEI's in-house TV studio or ISDN facilities, please contact:


TV Jesse Blumenthal [email protected] / 202.862.4870


Radio Michael Pratt [email protected] / 202.862.5823


Print or Web Jesse Blumenthal [email protected] / 202.862.4870, Michael Pratt at [email protected] / 202.862.5823, or Veronique Rodman at [email protected] / 202.862.4871


Follow @AEInews

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Scott
Gottlieb

What's new on AEI

Rebuilding American defense: A speech by Governor Bobby Jindal
image Smelling liberal, thinking conservative
image Stopping Ebola before it turns into a pandemic
image All too many reasons for pessimism about Europe
AEI on Facebook
Events Calendar
  • 20
    MON
  • 21
    TUE
  • 22
    WED
  • 23
    THU
  • 24
    FRI
Monday, October 20, 2014 | 2:00 p.m. – 3:30 p.m.
Warfare beneath the waves: The undersea domain in Asia

We welcome you to join us for a panel discussion of the undersea military competition occurring in Asia and what it means for the United States and its allies.

Event Registration is Closed
Tuesday, October 21, 2014 | 8:30 a.m. – 10:00 a.m.
AEI Election Watch 2014: What will happen and why it matters

AEI’s Election Watch is back! Please join us for two sessions of the longest-running election program in Washington, DC. 

Event Registration is Closed
Wednesday, October 22, 2014 | 1:00 p.m. – 2:30 p.m.
What now for the Common Core?

We welcome you to join us at AEI for a discussion of what’s next for the Common Core.

Thursday, October 23, 2014 | 10:00 a.m. – 11:00 a.m.
Brazil’s presidential election: Real challenges, real choices

Please join AEI for a discussion examining each candidate’s platform and prospects for victory and the impact that a possible shift toward free-market policies in Brazil might have on South America as a whole.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.